Rhumbline Advisers raised its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 58.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the quarter. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter.
Analysts Set New Price Targets
A number of brokerages have issued reports on CANF. StockNews.com began coverage on Can-Fite BioPharma in a research note on Friday, March 7th. They set a “sell” rating for the company. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Monday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.
Read Our Latest Report on CANF
Can-Fite BioPharma Trading Up 2.9 %
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Further Reading
- Five stocks we like better than Can-Fite BioPharma
- High Flyers: 3 Natural Gas Stocks for March 2022
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- CD Calculator: Certificate of Deposit Calculator
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- The Basics of Support and Resistance
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Want to see what other hedge funds are holding CANF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report).
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.